Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

GE Healthcare

- PMLiVE

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

BiTE will rival therapies from Bluebird, Celgene/Juno, J&J/Legend biotech

- PMLiVE

Astellas, Catalyst approvals set up record year for FDA approvals

2018 is already well ahead of last year's tally

- PMLiVE

Chi-Med and Lilly’s cancer drug Elunate a milestone for China

Partners tap into expanding market - but have multinationals to compete with

Roche Basel Switzerland

Roche builds on Immunocore ImmTAC deal

Extends partnership to target MAGE-A4 protein tumours

- PMLiVE

AZ drug matched to cancer mutation passes phase 2 test

More data from promising class of targeted small molecule drugs

- PMLiVE

Roche gains speedy review for Tecentriq in first-line breast cancer

Set to become the first immunotherapy for triple negative breast cancer

- PMLiVE

Soon-Shiong presents first data on cancer memory vaccine at SITC

Novel cocktail shows modest gains in prostate cancer

Roche Basel Switzerland

Roche and AbbVie prepare to move Venclexta into first-line CLL

Data shows an extended PFS compared to those on Gazyva plus chlorambucil chemo

- PMLiVE

Is GSK planning to exit the respiratory business?

Oncology head says opportunities diminishing despite firm's heritage

- PMLiVE

BMS CEO tackles investor ‘frustrations’ on immuno-oncology

Company faces pressure from competitors in renal cell carcinoma

- PMLiVE

Roche’s new flu pill Xofluza approved in US

First novel treatment in decades, but hasn't shown superiority to Tamiflu

- PMLiVE

AZ swells immuno-oncology pipeline with Innate deal

Deal gives access to natural killer cell immunotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links